Evidence map›Paper›PMID 39034892›Full record

ArticleESC heart failure2024

Immune cell profiling of the ICAM1 p.K56M heart failure with preserved ejection fraction risk variant.

Jing Gao, Pedro Giro, Joseph A Delaney, Laura Rasmussen-Torvik, Kent D Taylor, Edward B Thorp, Margaret F Doyle, Matthew J Feinstein, Colleen M Sitlani, Nels Olson and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jing GaoDivision of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Pedro GiroDivision of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Joseph A DelaneyDepartment of Epidemiology, University of Washington, Seattle, Washington, USA.
Laura Rasmussen-TorvikDepartment of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Kent D TaylorThe Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, USA.
Edward B ThorpDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Margaret F DoyleDepartment of Pathology and Laboratory Medicine, University of Vermont, Burlington, Vermont, USA.
Matthew J FeinsteinDivision of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Colleen M SitlaniCardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington, USA.
Nels OlsonDepartment of Pathology and Laboratory Medicine, University of Vermont, Burlington, Vermont, USA.
Russell TracyDepartment of Pathology and Laboratory Medicine, University of Vermont, Burlington, Vermont, USA.
Sanjiv J ShahDivision of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Bruce M PsatyCardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Systems and Population Health, University of Washington, Seattle, Washington, USA.
Ravi B PatelDivision of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Funding

Transgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Andrea L Hevener · 2003 to 2026
$40.4M
Task Area A Core Study Operations.Task Area A shall encompass annual follow-up of cohort members, clinical endpoints ascertainment, study coordination activities, maintenance of the database and biosp75N92020D00001 · NHLBI · UNIVERSITY OF WASHINGTON · PI MCCLELLAND, ROBYN LEAGH · 2020 to 2025
$17.2M
Plasma proteomics in CHS and population biologyR01HL144483 · NHLBI · UNIVERSITY OF WASHINGTON · PI DURDA, JON PETER, GERSZTEN, ROBERT E · 2019 to 2022
$6.0M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
TO EXERCISE OPTION PERIOD ONE (1) FOR TASK AREA A - MESA CORE OPERATIONS, FIELD CENTER.75N92020D00004 · NHLBI · NORTHWESTERN UNIVERSITY · PI SIEGEL, JONATHAN H · 2020 to 2025
$4.5M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00006 · NHLBI · UNIVERSITY OF MINNESOTA · PI PANKOW, JAMES S · 2020 to 2025
$4.4M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00003 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI POST, WENDY S · 2020 to 2025
$3.8M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00007 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BERTONI, ALAIN GERALD · 2020 to 2025
$3.5M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00002 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHEA, STEVEN J · 2020 to 2025
$3.4M
T-cell subsets as CVD risk factors in CHS and MESAR01HL120854 · NHLBI · UNIVERSITY OF WASHINGTON · PI PSATY, BRUCE M, TRACY, RUSSELL P · 2014 to 2017
$2.6M
Integrated Proteomic and Metabolomic Determinants of Left Atrial DysfunctionR01HL167986 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Ravi Bharat Patel · 2024 to 2026
$1.9M
CHIcago Center for Accelerating nextGen Omics, deep phenotyping, and data science in Heart Failure (CHICAGO-HF)U01HL160279 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Sadiya Sana Khan, Laura J Rasmussen-Torvik · 2021 to 2026
$1.8M
National Heart, Lung, and Blood Institute (NHLBI) N01-HC-65226National Heart, Lung, and Blood Institute (NHLBI) N02-HL-64278NHLBI NIH HHS 75N92020D00001NHLBI NIH HHS 75N92020D00002NHLBI NIH HHS 75N92020D00003NHLBI NIH HHS 75N92020D00004NHLBI NIH HHS 75N92020D00005NHLBI NIH HHS 75N92020D00006NHLBI NIH HHS 75N92020D00007NHLBI NIH HHS HHSN268201500003CNHLBI NIH HHS HHSN268201500003INHLBI NIH HHS N01 HC095169NHLBI NIH HHS R00 HL129045NHLBI NIH HHS R01 HL120854NHLBI NIH HHS R01 HL144483NHLBI NIH HHS R01 HL167986NHLBI NIH HHS U01 HL160279NIDDK NIH HHS P30 DK063491NIH HHS R00HL129045NIH HHS R01HL120854NIH HHS R01HL144483NIH HHS R01HL167986
6 · The paper itself

Abstract

aimsIntercellular adhesion molecule-1 (ICAM-1) facilitates inflammation via leucocyte recruitment and has been implicated in heart failure with preserved ejection fraction (HFpEF). Approximately 35% of African American individuals carry a copy of an ICAM1 missense variant (rs5491; p.K56M), which is associated with an increased risk of HFpEF. The pathways by which rs5491 increases HFpEF risk are not well defined. We evaluated the circulating immune cell profile of rs5491.

methodsAmong African American individuals in the Multi-Ethnic Study of Atherosclerosis, we evaluated the associations of rs5491 with 29 circulating peripheral blood mononuclear cell subsets. The top immune cells were then related to echocardiographic measures of structure and function.

resultsAmong 502 individuals with immune cell profiling (mean age 63 years, 51% female), 191 individuals (38%) had at least one copy of rs5491. Each additional rs5491 allele was significantly associated with higher proportions of Tc17 CD8

conclusionsThe ICAM1 p.K56M variant (rs5491) carries a distinct and inflammatory T-cell subset profile. These cytotoxic T cells are in turn associated with alterations in cardiac function and adverse haemodynamics later in life, thus providing insight into pathways by which rs5491 may increase the risk of HFpEF.

Indexed as

Heart FailureIntercellular Adhesion Molecule-1Stroke VolumeAgedBlack or African AmericanDNAEchocardiographyFemaleHumansMaleMiddle AgedVentricular Function, LeftDNAICAM1 protein, humanIntercellular Adhesion Molecule-1echocardiographygeneticsheart failure with preserved ejection fractionimmune cellsintercellular adhesion molecule‐1

Identifiers

PMID39034892
PMCPMC11631225

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.